Literature DB >> 16137620

Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.

Qianben Wang1, Jason S Carroll, Myles Brown.   

Abstract

Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer, where it is a key therapeutic target. Here we report that, in contrast to estrogen receptor transcription complexes which form within minutes and recycle hourly, the levels of regulatory regions bound by AR complexes rise over a 16 hr period and then slowly decline. AR regulation of the prostate specific antigen (PSA) gene involves both a promoter-proximal sequence as well as an enhancer approximately 4 kb upstream. Recruitment of AR and its essential coactivators at both sites creates a chromosomal loop that allows RNA polymerase II (pol II) to track from the enhancer to the promoter. Phosphorylation of the pol II C-terminal domain is required for pol II tracking but not chromosomal looping. Development of improved hormonal therapies for prostate cancer must take in account the specific spatial and temporal modes of AR-mediated gene regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137620     DOI: 10.1016/j.molcel.2005.07.018

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  222 in total

1.  MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Authors:  Maroof Alam; Rehan Ahmad; Hasan Rajabi; Donald Kufe
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

2.  Dynamic nature of transcriptional regulation of nuclear receptor target genes in the context of chromatin organization.

Authors:  Sami Väisänen; Juha Matilainen; Carsten Carlberg
Journal:  Dermatoendocrinol       Date:  2011-07-01

3.  Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-{alpha}1 and involves targeted covalent histone modifications.

Authors:  Madesh Belakavadi; Jason Saunders; Noah Weisleder; Preethi S Raghava; Joseph D Fondell
Journal:  Endocrinology       Date:  2010-04-14       Impact factor: 4.736

Review 4.  Enhancer-promoter interference and its prevention in transgenic plants.

Authors:  Stacy D Singer; Kerik D Cox; Zongrang Liu
Journal:  Plant Cell Rep       Date:  2010-12-19       Impact factor: 4.570

Review 5.  The human Mediator complex: a versatile, genome-wide regulator of transcription.

Authors:  Dylan J Taatjes
Journal:  Trends Biochem Sci       Date:  2010-03-17       Impact factor: 13.807

6.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Authors:  Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  BRG1 requirement for long-range interaction of a locus control region with a downstream promoter.

Authors:  Shin-Il Kim; Scott J Bultman; Christine M Kiefer; Ann Dean; Emery H Bresnick
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

8.  Computational Approaches for Mining GRO-Seq Data to Identify and Characterize Active Enhancers.

Authors:  Anusha Nagari; Shino Murakami; Venkat S Malladi; W Lee Kraus
Journal:  Methods Mol Biol       Date:  2017

9.  Corepressive action of CBP on androgen receptor transactivation in pericentric heterochromatin in a Drosophila experimental model system.

Authors:  Yue Zhao; Ken-ichi Takeyama; Shun Sawatsubashi; Saya Ito; Eriko Suzuki; Kaoru Yamagata; Masahiko Tanabe; Shuhei Kimura; Sally Fujiyama; Takashi Ueda; Takuya Murata; Hiroyuki Matsukawa; Yuko Shirode; Alexander P Kouzmenko; Feng Li; Testuya Tabata; Shigeaki Kato
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

Review 10.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.